Belova L A, Mashin V V, Dudikov E M, Belov D V, Krupennikov A A
Ulyanovsk State University, Ulyanovsk, Russia.
Zh Nevrol Psikhiatr Im S S Korsakova. 2019;119(2):35-38. doi: 10.17116/jnevro201911902135.
To make a critical assessment of the therapeutic effect of complex therapy with cortexin and recognan (citicoline) for cognitive impairments in patients with chronic cerebrovascular pathology.
Presented is an analysis of results of the multicenter observation program to assess the efficacy of cortexin and recognan (citicoline) in the treatment of cognitive impairments in patients with chronic cerebrovascular pathology. Three hundred and nine patients with chronic cerebrovascular pathology, including 134 (43.4%) men and 175 (56.6%) women, aged from 30 to 80, average age 63.4±9.4 years, with confirmed cognitive deficit were examined. The diagnosis was established on the basis of complaints, case reports, the results of CT/MRI studies, as well as assessments of the neurological status and cognitive functions. Cognitive impairments were confirmed by the number of points on the Mini-mental state examination (MMSE) and the Clock drawing test. The assessment of depression was made with the Mini Geriatric Depression Scale (MGDS). All patients received cortexin and recognan (citicoline) ('Geropharm', Russia) at doses 10 mg/day for 10 days and 1000 mg/day for 1 month, respectively.
Complex therapy with cortexin and recognan (citicoline) showed high efficacy in the treatment of vascular cognitive disorders. The results of the study allow us to recommend the complex administration of cortexin and recognan (citicoline) ('Geropharm', Russia) in doses of 10 mg/day for 10 days and 1000 mg/day for 1 month, respectively, for chronic cerebrovascular pathology.
对使用皮质素和胞磷胆碱复合疗法治疗慢性脑血管病患者认知障碍的疗效进行批判性评估。
呈现了一项多中心观察项目的结果分析，以评估皮质素和胞磷胆碱（俄罗斯“杰罗芬”）治疗慢性脑血管病患者认知障碍的疗效。对309例慢性脑血管病患者进行了检查，其中男性134例（43.4%），女性175例（56.6%），年龄在30至80岁之间，平均年龄63.4±9.4岁，认知缺陷得到确诊。诊断基于患者主诉、病例报告、CT/MRI检查结果以及神经学状态和认知功能评估。通过简易精神状态检查表（MMSE）得分和画钟试验确认认知障碍。使用简易老年抑郁量表（MGDS）评估抑郁情况。所有患者分别接受剂量为10毫克/天，共10天的皮质素和剂量为1000毫克/天，共1个月的胞磷胆碱（俄罗斯“杰罗芬”）治疗。
皮质素和胞磷胆碱复合疗法在治疗血管性认知障碍方面显示出高效性。该研究结果使我们推荐，对于慢性脑血管病，分别以10毫克/天，共10天和1000毫克/天，共1个月的剂量联合使用皮质素和胞磷胆碱（俄罗斯“杰罗芬”）。
